Ovarian Cancer: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or
Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary
What are good and bad effects of adding atezolizumab to the usual chemotherapy (liposomal
doxorubicin) and to the usual chemotherapy with bevacizumab?
Basic Study Information
Purpose:Location: Cancer Center
This study has 3 study groups, a computer will assign you to a study group by chance.
There is an equal chance of receiving each treatment. This is done by chance, because
no one knows if one study group is better or worse than the others. Group 1 will get
an experimental chemotherapy treatment (liposomal doxorubicin and atezolizumab), group
2 will get an experimental chemotherapy treatment (liposomal doxorubicin and bevacizumab
plus atezolizumab), and group 3 will get a usual chemotherapy treatment for this type
of cancer (liposomal doxorubicin and bevacizumab). The liposomal doxorubicin will
be given into your vein over approximately 60 minutes. The bevacizumab will be given
into your vein over approximately 90 minutes initially, then faster at later visits
if administration goes smoothly at the slower rates. The atezolizumab will be given
into your vein over approximately 60 minutes initially, then faster at later visits
if administration goes smoothly at the slower rates. Treatment will be given on days
1 and 15 of each 28-day period. This period of time is called a cycle, which is a
regular schedule of treatment with periods of rest in between.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02839707?term=GY009&rank=1
Study Reference #: CGYO18021
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search